Next Article in Journal
Insidious-Onset Indurated Plaques on the Shins
Previous Article in Journal
How to Deal with Skin Biopsy in an Infant with Blisters?
Article

5-Hydroxymethylcytosine Loss in Conjunctival Melanoma

1
Jules-Gonin Eye Hospital, Lausanne University, 1004 Lausanne, Switzerland
2
Experimental Pathology, University Hospital of Lausanne (CHUV), 1011 Lausanne, Switzerland
3
Dermatopathology Unit, Dermatology and Clinical Pathology Departments, University Hospitals of Geneva, 1205 Geneva, Switzerland
*
Author to whom correspondence should be addressed.
Academic Editor: Franco Rongioletti
Received: 22 April 2021 / Revised: 28 May 2021 / Accepted: 2 June 2021 / Published: 5 June 2021
(This article belongs to the Section Clinico-Pathological Correlation in Dermatopathology)
Aims: Conjunctival and cutaneous melanoma partially share similar clinical and molecular backgrounds. As 5-hydroxymethylcytosine (5-hmC) loss has been demonstrated in cutaneous melanoma, we decided to assess if similar changes were occurring in conjunctival melanoma. Methods: 5-methylcytosine (5-mC), 5-hmC and TET2 were respectively identified by immunohistochemistry and RNA ISH in 40 conjunctival nevi and 37 conjunctival melanomas. Clinicopathological correlations were established. Results: 5-mC, TET2 and 5-hmC were respectively identified in 67.5%, 95% and 100% of conjunctival nevi and in 81.1%, 35.1% and 54% of conjunctival melanomas. A significant 5-hmC and TET2 loss was identified in conjunctival melanoma comparing to nevus, as well as a significant correlation between TET2 and 5-hmC expression. In the melanomas, 5-hmC expression was only significantly associated with local lymphatic invasion, but not with other clinicopathological parameters. There was a correlation between TET2 expression and the localization of the tumors. 5-mC expression was not associated with any clinicopathological parameters. Conclusions: We identified a significant 5-hmC loss in conjunctival melanoma similar to cutaneous melanoma. This loss may possibly be attributed to TET2 loss or IDH1 mutations. 5-hmC loss in conjunctival melanoma may help in the differential diagnosis between atypical conjunctival nevus and conjunctival melanoma. View Full-Text
Keywords: conjunctival melanoma; epigenetics; 5-hydroxymethylcytosine; 5-methylcytosine; TET2 conjunctival melanoma; epigenetics; 5-hydroxymethylcytosine; 5-methylcytosine; TET2
Show Figures

Figure 1

MDPI and ACS Style

Stahl, A.; Riggi, N.; Nardou, K.; Nicolas, M.; Kaya, G.; Moulin, A. 5-Hydroxymethylcytosine Loss in Conjunctival Melanoma. Dermatopathology 2021, 8, 176-184. https://0-doi-org.brum.beds.ac.uk/10.3390/dermatopathology8020023

AMA Style

Stahl A, Riggi N, Nardou K, Nicolas M, Kaya G, Moulin A. 5-Hydroxymethylcytosine Loss in Conjunctival Melanoma. Dermatopathology. 2021; 8(2):176-184. https://0-doi-org.brum.beds.ac.uk/10.3390/dermatopathology8020023

Chicago/Turabian Style

Stahl, Alexandre, Nicolo Riggi, Katya Nardou, Michael Nicolas, Gurkan Kaya, and Alexandre Moulin. 2021. "5-Hydroxymethylcytosine Loss in Conjunctival Melanoma" Dermatopathology 8, no. 2: 176-184. https://0-doi-org.brum.beds.ac.uk/10.3390/dermatopathology8020023

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop